KRAS and non-small cell lung carcinoma: Another study of ICIs treating NSCLC patients with high programmed death ligand 1 (PD-L1) expression showed that the KRAS mutation status had no significant impact on the efficacy or safety of ICIs, though with a non-significant trend of worse survival in patients with KRAS G12C mutations [40].